Abstracts tagged "Biologic agents"

Abstract Number: 1338 • 2016 ACR/ARHP Annual Meeting
Use of Subcutaneous Golimumab in Autoimmune Inner Ear Disease
Deeba Minhas¹, Michele Gandolfi², Jennifer Derebery³, Eric Wilkinson³ and Mariko Ishimori¹, ¹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ²Otology, House Clinic, Los Angeles, CA, ³House Clinic, Los Angeles, CA
Background/Purpose: Autoimmune Inner Ear Disease (AIED) is characterized by rapidly progressive sensorineural hearing loss accompanied by tinnitus, with or without vertigo, which may progress to…
Abstract Number: 1999 • 2016 ACR/ARHP Annual Meeting
Claims-Based Analysis of Cost-Effectiveness Among Patients with Rheumatoid Arthritis Who Switched from a Tumor Necrosis Factor Inhibitor to Another Targeted Disease-Modifying Antirheumatic Drug
Machaon Bonafede¹, Wenhui Wei², Chieh-I Chen³, Donna McMorrow¹, Stefano Fiore⁴, Jonathan Fay³, Toshio Kimura³ and Jeffrey R. Curtis⁵, ¹Truven Health Analytics, Cambridge, MA, ²Sanofi US, Inc., Bridgewater, NJ, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Sanofi Genzyme, Bridgwater, NJ, ⁵Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Patients with rheumatoid arthritis (RA) who have an inadequate response to a tumor necrosis factor inhibitor (TNFi) can switch to another targeted disease-modifying antirheumatic…
Abstract Number: 2611 • 2016 ACR/ARHP Annual Meeting
Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
Seoyoung C. Kim¹, Daniel H. Solomon¹, James R. Rogers¹, Sara Gale², Micki Klearman², Khaled Sarsour² and Sebastian Schneeweiss¹, ¹Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ²Genentech, South San Francisco, CA
Background/Purpose: Patients with rheumatoid arthritis (RA) are at elevated risk for cardiovascular (CV) disease. Patients using tocilizumab (TCZ) may experience increased serum lipid levels. It…
Abstract Number: 2982 • 2016 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Inhibitors and the Risk of Malignancy in the Treatment of Juvenile Idiopathic Arthritis
Timothy Beukelman¹, Fenglong Xie², Lang Chen², Daniel Horton³, James D. Lewis⁴, Ronac Mamtani⁴, Melissa Mannion⁵, Kenneth G. Saag⁶, Jie Zhang⁷ and Jeffrey R. Curtis⁶, ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Pediatrics, University of Alabama at Birmingham, Birmingham, AL, ⁶Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Epidemilogy, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The possible association between tumor necrosis factor inhibitors (TNFi) in the treatment of juvenile idiopathic arthritis (JIA) and an increased risk of malignancy remains…
Abstract Number: 3L • 2015 ACR/ARHP Annual Meeting
A Randomised Controlled Trial of the Clinical Effectiveness, Safety and Cost-Effectiveness of Adalimumab in Combination with Methotrexate for the Treatment of Juvenile Idiopathic Arthritis Associated Uveitis
Athimalaipet V Ramanan¹, Andrew D. Dick², Andrew McKay³, Ashley Jones⁴, Paula Williamson⁴, Sandrine Compeyrot-Lacassagne⁵, Ben Hardwick⁴, Helen Hickey⁴, Dyfrig Hughes⁶, Patricia Woo⁵, Diana Benton¹, Clive Edelsten⁵ and Michael W. Beresford⁷, ¹University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom, ²University of Bristol, Bristol Eye Hospital, Bristol, United Kingdom, ³Biostatistics, Clinical Trials Research Centre, University of Liverpool, Liverpool, United Kingdom, ⁴Clinical Trials Research Centre, University of Liverpool, Liverpool, United Kingdom, ⁵Great Ormond Street Hospital, London, United Kingdom, ⁶Bangor University, Bangor, United Kingdom, ⁷University of Liverpool, Liverpool, United Kingdom
Background/Purpose: Uveitis associated with Juvenile Idiopathic Arthritis (JIA) is a major cause of morbidity with potentially sight-threatening complications. Despite current screening and (pre-biologic) therapeutic options,…
Abstract Number: 4L • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Epratuzumab in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized, Placebo-Controlled Trials
Megan E. B. Clowse¹, Daniel J Wallace², Richard Furie³, Michelle Petri⁴, Marilyn Pike⁵, Piotr Leszczynski⁶, C Michael Neuwelt⁷, Kathryn Hobbs⁸, Mauro Keiserman⁹, Liliana Duca¹⁰, Kenneth Kalunian¹¹, Sabine Bongardt¹², Christian Stach¹², Carolyn Beaudot¹³, Brian Kilgallen¹³, Catrinel Galateanu¹⁴ and Caroline Gordon^15,16, ¹Rheumatology, Duke University, Durham, NC, ²Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ³North Shore LIJ Health System, Manhasset, NY, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Med Pharm Consulting Inc, Cambridge, MA, ⁶Dept. of Rheumatology and Clinical Immunology, J. Strus Poznan Municipal Hospital, Poznan University of Medical Sciences, Poznan, Poland, ⁷Division of Rheumatology, Alameda County Medical Center, Oakland, CA, ⁸Denver Arthritis Clinic, Denver, CO, ⁹School of Medicine, Pontifical Catholic University, Porto Alegre, Brazil, ¹⁰Clinica Neomed, Brasov, Romania, ¹¹UCSD School of Medicine, La Jolla, CA, ¹²UCB Pharma, Monheim, Germany, ¹³UCB Pharma, Raleigh, NC, ¹⁴UCB Pharma, Brussels, Belgium, ¹⁵Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ¹⁶NIHR/Wellcome Trust Clinical Research Facility, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Background/Purpose: In phase 2b trials, epratuzumab, a humanized anti-CD22 mAb that modulates B cell signaling without total B cell depletion, significantly improved disease activity in…
Abstract Number: 443 • 2015 ACR/ARHP Annual Meeting
Drug Survival and Reasons for Discontinuation of Biological Disease Modifying Antirheumatic Drug in Thai Patients with Rheumatoid Arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization (RDPA) Register
Pongthorn Narongroeknawin¹, Wanruchada Katchamart², Parawee Suwannalai³, Nuntana Kasitanon⁴, Tasanee Kitumnuaypong⁵, Ajanee Mahakkanukrauh⁶ and Boonjing Siripaitoon⁷, ¹Rheumatic Disease Unit, Department of Internal Medicine, Phramongkutklao Hospital and Phramongkutklao College of Medicine, Bangkok, Thailand, ²Division of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj hospital, Mahidol University, Bangkok, Thailand, ³Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, ⁴Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, ⁵Rheumatology Unit, Department of Internal Medicine, Rajavithi Hospital, Bangkok, Thailand, ⁶Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand, ⁷Division of Rheumatology, Department of Medicine, Faculty of Medicine, Prince of Songkla University, Songkla, Thailand
Background/Purpose: To evaluate long-term efficacy and safety of biological disease modifying antirheumatic drug (bDMARD) in real-life practice and identify risk factors related to remission and drug discontinuation…
Abstract Number: 1040 • 2015 ACR/ARHP Annual Meeting
Factors Associated with Long Term Rituximab Use in Rheumatoid Arthritis – Results from the British Society of Rheumatology Biologics Register
Alexander G.S. Oldroyd¹, Deborah P.M. Symmons¹, Lianne Kearsley-Fleet¹, Kath Watson¹, Mark Lunt², Jamie Sergeant¹, Kimme L. Hyrich¹ and on behalf of the BSRBR-RA, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Analysis of long term continuation of biologics in rheumatoid arthritis (RA) is considered a valid surrogate for treatment effectiveness and safety. Only a small…
Abstract Number: 1651 • 2015 ACR/ARHP Annual Meeting
Comparison of Oral Glucocorticoid (OGC)-Sparing Effects in Tocilizumab and Other Biologic Dmards Using Multilevel Models in an Administrative Health Care Claims Database
Brandon Arnieri¹, Khaled Sarsour¹, David Oliveri¹, Attila Pethö-Schramm², Avani Shah¹ and George Quartey¹, ¹Genentech, South San Francisco, CA, ²F. Hoffmann-La Roche, Basel, Switzerland
Background/Purpose : The current treatment paradigm in rheumatoid arthritis (RA) is to attempt to decrease, when clinically feasible, concomitant use of OGCs after their use…
Abstract Number: 2759 • 2015 ACR/ARHP Annual Meeting
Long-Term Survival of Biological Therapy in Rheumatoid Arthritis Elderly Patients in Clinical Practice
Cristina Lajas¹, Alejandro Gomez-Gomez¹, Luis Rodriguez-Rodriguez², Leticia Leon², Cristina Vadillo¹, Dalifer Freites Núñez¹, Pilar Macarrón¹, José María Leal Pozuelo², Juan A Jover¹ and Lydia Abasolo², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose: With the increasingly widespread use of biological agents (BA), a thorough knowledge of their long-term behavior in clinical practice is fundamental. The purpose of…
Abstract Number: 445 • 2015 ACR/ARHP Annual Meeting
Persistence with Biologic Monotherapy in Comparison with Combination Therapy with Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis; Results from a Rheumatoid Arthritis Cohort
Arthur Lau¹, Mohammad Movahedi^2,3, Mark Tatangelo⁴, Claire Bombardier^3,5,6 and OBRI investigators, ¹Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ²JSS Medical Research, St-Laurent, QC, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴Clinical Decision Making and Health Care, Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁵University of Toronto, Department of Medicine (DOM) and Institute of Health Policy Management, and Evaluation (IHPME), Toronto, ON, Canada, ⁶Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Clinical evidence suggests concomitant treatment with a biologic Disease-Modifying Antirheumatic Drug (bDMARD) and a conventional synthetic DMARD (csDMARD), especially with methotrexate (MTX) has greater…
Abstract Number: 1046 • 2015 ACR/ARHP Annual Meeting
Previous Biologic Disease-Modifying Antirheumatic Drug (bDMARD) Exposure and Efficacy and Safety Analysis from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors
Mark C. Genovese¹, Joel M. Kremer², Cynthia Kartman³, Douglas E. Schlichting³, Li Xie³, Tara Carmack⁴, William L. Macias³ and Josef S. Smolen⁵, ¹Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA, ²Center for Rheumatology, Albany, NY, ³Eli Lilly and Company, Indianapolis, IN, ⁴Quintiles, Durham, NC, ⁵Department of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Baricitinib, an oral inhibitor of JAK1/JAK2, improved disease activity with an acceptable safety profile in a phase 3 study (RA-BEACON) of patients with active…
Abstract Number: 1654 • 2015 ACR/ARHP Annual Meeting
A Systematic Review and Network Meta-Analysis on the Efficacy of Tumor Necrosis Factor Inhibitor-Methotrexate Combination Therapy Versus Triple Therapy in Methotrexate-Naïve Patients with Rheumatoid Arthritis
Roy Fleischmann¹, Janet E. Pope², Vanita Tongbram³, Derek Tang⁴, James Chung⁵, David Collier⁵, Shilpa Urs³, Kerigo Ndirangu³, George A. Wells⁶ and Ronald F. van Vollenhoven⁷, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²University of Western Ontario, London, ON, Canada, ³ICON Plc., Morristown, NJ, ⁴Amgen, Inc., Thousand Oaks, CA, ⁵Amgen Inc., Thousand Oaks, CA, ⁶Cardiovascular Research Reference Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada, ⁷Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden
Background/Purpose: Several published randomized head-to-head trials in rheumatoid arthritis (RA) have compared TNFi-MTX with triple therapy (MTX + hydroxychloroquine + sulfasalazine) in MTX-naive patients (MTX-Ns)…
Abstract Number: 2764 • 2015 ACR/ARHP Annual Meeting
Head-to-Head Comparison of the Retention Rate of First Biologics in Elderly Patients with Rheumatoid Arthritis in Japanese Clinical Practice: Results from the Multicenter Biologic Registry
Masatoshi Hayashi¹, Toshihisa Kanamono², Hiroyuki Matsubara³, Toshihisa Kojima⁴, Koji Funahashi⁵, Nobunori Takahashi⁴ and Naoki Ishiguro⁶, ¹Departments of Orthopedic surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ²Reumatology, Nagano Red Cross Hospital, Nagano, Japan, ³Department of Orthopedic Surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ⁴Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ⁵Nagoya University, Nagoya, Japan, ⁶Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: The objective of this report was to clarify and compare the retention rate of first biologics used to treat elderly Japanese patients with rheumatoid…
Abstract Number: 477 • 2015 ACR/ARHP Annual Meeting
On-Demand Use of Etanercept Only for Disease Flares Reduced the Disease Activity Score and Structural Damage Equivalent to Fully-Use of Etanercept in RA Patients
Kentaro Inui¹, Tatsuya Koike², Masahiro Tada³, Yuko Sugioka², Kenji Mamoto⁴, Tadashi Okano⁴, Akira Sakawa⁵, Kenzo Fukushima⁶ and Hiroaki Nakamura⁴, ¹Orthopaedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ²Center for Senile Degenerative Disorders (CSDD), Osaka City University Graduate School of Medicine, Osaka, Japan, ³Orthopaedic Surgery, Osaka City General Hospital, OSAKA, Japan, ⁴Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ⁵Orthopaedic Surgery, Osaka City Juso Hospital, Osaka, Japan, ⁶Orthopaedic Surgery, Fujiidera Municipal Hospital, Fujiidera, Japan
Background/Purpose: Biological disease-modifying antirheumatic drugs (bDMARDs) are essential in the treatment of rheumatoid arthritis (RA). Biological DMARDs are particularly recommended for patients with active RA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].